ARS Pharmaceuticals Operations, Inc.

The journey of ARS Pharmaceuticals began in 2015, born from a mission to revolutionize the way severe allergic reactions are treated. Co-founded by Richard Lowenthal, who now serves as President and CEO, the company was established with a clear and powerful vision: to empower patients and their caregivers with a needle-free, easy-to-use, and reliable solution for life-threatening allergic emergencies. For decades, the standard of care for anaphylaxis had been the epinephrine auto-injector, a device that, while effective, often caused fear and hesitation in patients and caregivers, particularly when treating children. This hesitation could lead to dangerous delays in treatment. Recognizing this significant unmet need, the team at ARS embarked on a dedicated path to develop an alternative that would remove the barrier of needle-phobia and anxiety associated with injections.

This commitment led to the creation of 'neffy' (epinephrine nasal spray), a groundbreaking product representing the first major innovation in epinephrine delivery in over 35 years. The development of neffy was a meticulous process, involving extensive research, numerous clinical trials, and a steadfast focus on patient-centric design. The result is a proprietary composition of epinephrine combined with an absorption enhancer, Intravail®, allowing for injection-like absorption in a simple nasal spray. This innovative approach provides a small, easy-to-carry device that can be administered quickly and confidently at the first signs of a severe allergic reaction. After years of diligent work and navigating the rigorous regulatory landscape, ARS Pharmaceuticals achieved a monumental milestone with the FDA approval of neffy. This achievement was not just a corporate success but a victory for the millions of individuals living with the daily threat of anaphylaxis, offering them newfound peace of mind and a more accessible, less intimidating method of emergency treatment. The company continues its journey, driven by a passion to make a meaningful impact on the lives of those affected by severe allergies worldwide.